Verapamil
Verapamil - Related Videos
05:22
Cancer Side Population Discrimination Assay: A Method to Isolate Cancer Stem-like Cells Using Hoechst Dye Efflux Assay
0 Views •
2023
In this video, we describe the isolation of a subpopulation of cancer stem-like cells from head and neck squamous carcinoma cell lines using fluorescence-activated cell sorter or FACS. The isolated side population of cells can be used for further downstream analysis.
12:25
Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells
0 Views •
2026
Here, we present a protocol for generating chemoresistant cells using a dose-escalation approach, followed by a CRISPR/Cas9-based screen using a focused sgRNA library targeting epigenetic modifiers to identify regulators of acquired chemoresistance. The protocol also provides multiple optimization points tailored to chemoresistant cell models, offering a robust framework for researchers investigating resistance mechanisms.
04:31
Side Population Assay: A Method to Isolate Side Population of Tumor Cells from Zebrafish
0 Views •
2023
The following protocol describes a method for isolating the side population of T-cell Acute Lymphoblastic Leukemia (T-ALL) tumor cells, consisting of stem cells, from an adult Zebrafish. The side population lacks prominent cell markers and hence we use Hoechst 33342 dye efflux assay to isolate them.
08:56
Isolation of Murine Embryonic Hemogenic Endothelial Cells
0 Views •
Cited by 11 •
2016
Hematopoietic stem and progenitor cells (HSPC) derive from specialized (hemogenic) endothelial cells during development, yet little is known about the process by which some endothelial cells specify to become blood forming. We demonstrate a flow-cytometry based method allowing simultaneous isolation of hemogenic endothelial cells and HSPC from murine embryonic tissues.
11:28
Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics
0 Views •
Cited by 15 •
2016
Understanding the role of cancer stem-like cells in tumor recurrence and resistance to therapies has become a topic of great interest in the last decade. This article describes the isolation and characterization of the sub-population of cancer stem-like cells from head and neck squamous carcinoma cell lines (HNSCC).
FAQs
The outcome depends on which L-type calcium channel population is affected. In cardiac muscle, reduced calcium entry lowers contractility; in the atrioventricular node, it slows conduction; and in vascular smooth muscle, it promotes relaxation. Considering these sites separately helps pharmacologists connect one molecular action with changes in pumping strength, electrical transmission, and vascular resistance.
The atrioventricular node provides a clear example of how calcium-channel modulation changes cardiac electrical activity. Verapamil slows conduction through this region, which can reduce the transmission of rapid atrial activity to the ventricles. This mechanism explains its relevance to selected supraventricular tachyarrhythmias and illustrates why conduction effects must be distinguished from changes in contractility.
Verapamil is pharmacologically important because its effects are not confined to vascular smooth muscle. It also acts on cardiac muscle and the atrioventricular node, producing reduced contractility and slower conduction in addition to vasodilation. This broader cardiovascular profile allows researchers to compare changes in vascular resistance with effects on myocardial performance and cardiac electrical transmission.
The same calcium-entry modulation that slows atrioventricular conduction can become clinically significant when cardiac electrical activity is already vulnerable. Verapamil therefore illustrates how a therapeutic mechanism may produce an adverse response if conduction is reduced excessively. In pharmacology studies, heart rate and conduction are interpreted alongside contractility and vascular effects rather than treated as isolated outcomes.
A useful workflow begins by identifying L-type calcium channels as the molecular target, then examines effects in cardiac muscle, the atrioventricular node, and vascular smooth muscle. Researchers next relate those cellular actions to contractility, conduction, heart rate, and vascular resistance. This sequence provides a structured way to connect mechanism with therapeutic effects and possible adverse responses.
Verapamil is useful when a study needs to connect ion-channel pharmacology with clinically recognizable cardiovascular outcomes. Its effects provide context for hypertension, angina, and selected supraventricular tachyarrhythmias, while its potential to cause bradycardia or impaired conduction highlights safety considerations. The drug also supports discussion of how drug interactions can modify therapeutic or adverse responses.
Assessment should distinguish myocardial contractility, atrioventricular conduction, heart rate, and vascular resistance. These measures represent different physiological consequences of L-type calcium-channel inhibition and may not change in the same way. Comparing them helps clarify whether an observed response reflects cardiac pumping, electrical transmission, or vascular relaxation, strengthening interpretation of verapamil experiments and clinical pharmacology.
Verapamil shows how one molecular intervention can support several therapeutic applications through distinct physiological pathways. Reduced vascular resistance relates to hypertension, while effects on cardiac activity and atrioventricular conduction provide context for angina and selected supraventricular tachyarrhythmias. At the same time, adverse responses such as bradycardia demonstrate why mechanism-based benefits must be evaluated with cardiovascular limitations.